Feasibility of temporary protective embolization of normal liver tissue using degradable starch microspheres during radioembolization of liver tumours

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 2, 2014, Pages 231-237

  Meyer, Carsten ^a   Pieper, Claus Christian ^a   Ezziddin, Samer ^a   Wilhelm, Kai E ^a   Schild, Hans Heinz ^a   Ahmadzadehfar, Hojjat ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Degradable starch microspheres; EmboCept S; Radioembolization; Selective internal radiation therapy

Indexed keywords

EMBOCEPT S; FLUORODEOXYGLUCOSE F 18; IRINOTECAN; STARCH MICROSPHERE; TECHNETIUM 99M; UNCLASSIFIED DRUG; YTTRIUM 90;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; BILE DUCT CARCINOMA; BREMS RADIATION; CANCER RADIOTHERAPY; CHEMOEMBOLIZATION; COLORECTAL CARCINOMA; COMPARATIVE STUDY; CT SPECT SCANNER; FEMALE; FOLLOW UP; HUMAN; IRRADIATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PET-CT SCANNER; RADIOEMBOLIZATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; EMBOLIZATION, THERAPEUTIC; FEASIBILITY STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; STARCH; TECHNETIUM TC 99M AGGREGATED ALBUMIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; YTTRIUM RADIOISOTOPES;

EID: 84897090633     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2550-4     Document Type: Article

References (33)

1. Goin JE, Salem R, Carr BI, Dancey JE, Soulen MC, Geschwind JF, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol. 2005;16:205-13.
2. Salem R, Lewandowski RJ, Atassi B, Gordon SC, Gates VL, Barakat O, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol. 2005;16:1627-39.
3. Murthy R, Nunez R, Szklaruk J, Erwin W, Madoff DC, Gupta S, et al. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics. 2005;25 Suppl 1:S41-55.
4. Ahmadzadehfar H, Biersack HJ, Ezziddin S. Radioembolization of liver tumors with yttrium-90 microspheres. Semin Nucl Med. 2010;40: 105-21.
5. Riaz A, Lewandowski RJ, Kulik LM, Mulcahy MF, Sato KT, Ryu RK, et al. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol. 2009;20:1121-30.
6. Piana PM, Gonsalves CF, Sato T, Anne PR, McCann JW, Bar Ad V, et al. Toxicities after radioembolization with yttrium-90 SIR-spheres: incidence and contributing risk factors at a single center. J Vasc Interv Radiol. 2011;22:1373-9.
7. Ahmadzadehfar H, Mohlenbruch M, Sabet A, Meyer C, Muckle M, Haslerud T, et al. Is prophylactic embolization of the hepatic falciform artery needed before radioembolization in patients with (99m)Tc-MAA accumulation in the anterior abdominal wall? Eur J Nucl Med Mol Imaging. 2011;38:1477-84.
8. Ahmadzadehfar H, Sabet A, Biermann K, Muckle M, Brockmann H, Kuhl C, et al. The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment. J Nucl Med. 2010;51:1206-12.
9. Lenoir L, Edeline J, Rolland Y, Pracht M, Raoul JL, Ardisson V, et al. Usefulness and pitfalls of MAA SPECT/CT in identifying digestive extrahepatic uptake when planning liver radioembolization. Eur J Nucl Med Mol Imaging. 2012;39:872-80.
10. Ahmadzadehfar H, Sabet A, Muckle M, Wilhelm K, Reichmann K, Biersack HJ, et al. 99mTc-MAA/90Y-Bremsstrahlung SPECT/CT after simultaneous Tc-MAA/90Y-microsphere injection for immediate treatment monitoring and further therapy planning for radioembolization. Eur J Nucl Med Mol Imaging. 2011;38:1281-8.
11. Uliel L, Royal HD, Darcy MD, Zuckerman DA, Sharma A, Saad NE. From the angio suite to the gamma-camera: vascular mapping and 99mTc-MAA hepatic perfusion imaging before liver radio-embolization - a comprehensive pictorial review. J Nucl Med. 2012;53:1736-47.
12. Hogberg J, Rizell M, Hultborn R, Svensson J, Henrikson O, Gjertsson P, et al. Radiation exposure during liver surgery after treatment with (90)Y microspheres, evaluated with computer simulations and dosimeter measurements. J Radiol Prot. 2012;32:439-46.
13. Ahmadzadehfar H, Sabet A, Meyer C, Habibi E, Biersack HJ, Ezziddin S. The importance of Tc-MAA SPECT/CT for therapy planning of radioembolization in a patient treated with bevacizumab. Clin Nucl Med. 2012;37:1129-30.
14. Forsberg JO. Transient blood flow reduction induced by intra-arterial injection of degradable starch microspheres. Experiments on rats. Acta Chir Scand. 1978;144:275-81.
15. Ingold JA, Reed GB, Kaplan HS, Bagshaw MA. Radiation hepatitis. Am J Roentgenol Radium Ther Nucl Med. 1965;93:200-8.
16. Fajardo LF, Colby TV. Pathogenesis of veno-occlusive liver disease after radiation. Arch Pathol Lab Med. 1980;104:584-8.
17. Lewin K, Millis RR. Human radiation hepatitis. A morphologic study with emphasis on the late changes. Arch Pathol. 1973;96:21-6.
18. Hilgard P, Muller S, Hamami M, Sauerwein WS, Haberkorn U, Gerken G, et al. Selective internal radiotherapy (radioembolization) and radiation therapy for HCC - current status and perspectives. Z Gastroenterol. 2009;47:37-54.
19. Jakobs TF, Hoffmann RT, Dehm K, Trumm C, Stemmler HJ, Tatsch K, et al. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. J Vasc Interv Radiol. 2008;19:1187-95.
20. Atassi B, Bangash AK, Lewandowski RJ, Ibrahim S, Kulik L, Mulcahy MF, et al. Biliary sequelae following radioembolization with yttrium-90 microspheres. J Vasc Interv Radiol. 2008;19:691-7.
21. Strigari L, Sciuto R, Rea S, Carpanese L, Pizzi G, Soriani A, et al. Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations. J Nucl Med. 2010;51:1377-85.
22. Salem R, Hunter RD. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma: a review. Int J Radiat Oncol Biol Phys. 2006;66:S83-8.
23. de Luis E, Bilbao JI, de Ciercoles JA, Martinez-Cuesta A, de Martino Rodriguez A, Lozano MD. In vivo evaluation of a new embolic spherical particle (HepaSphere) in a kidney animal model. Cardiovasc Intervent Radiol. 2008;31:367-76.
24. Sakamoto I, Iwanaga S, Nagaoki K, Matsuoka Y, Ashizawa K, Uetani M, et al. Intrahepatic biloma formation (bile duct necrosis) after transcatheter arterial chemoembolization. AJR Am J Roentgenol. 2003;181:79-87.
25. Yu JS, Kim KW, Jeong MG, Lee DH, Park MS, Yoon SW. Predisposing factors of bile duct injury after transcatheter arterial chemoembolization (TACE) for hepatic malignancy. Cardiovasc Intervent Radiol. 2002;25:270-4.
26. Van de Wiele C, Maes A, Brugman E, D'Asseler Y, De Spiegeleer B, Mees G, et al. SIRTof liver metastases: physiological and pathophysiological considerations. Eur J Nucl Med Mol Imaging. 2012;39: 1646-55.
27. McWilliams JP, Kee ST, Loh CT, Lee EW, Liu DM. Prophylactic embolization of the cystic artery before radioembolization: feasibility, safety, and outcomes. Cardiovasc Intervent Radiol. 2011;34:786-92.
28. Theysohn JM, Muller S, Schlaak JF, Ertle J, Schlosser TW, Bockisch A, et al. Selective internal radiotherapy (SIRT) of hepatic tumors: how to deal with the cystic artery. Cardiovasc Intervent Radiol. 2013;36:1015-22.
29. Pohlen U, Buhr HJ, Berger G, Ritz JP, Holmer C. Hepatic arterial infusion (HAI) with PEGylated liposomes containing 5-FU improves tumor control of liver metastases in a rat model. Invest New Drugs. 2012;30:927-35.
30. Wang J, Murata S, Kumazaki T. Liver microcirculation after hepatic artery embolization with degradable starch microspheres in vivo. World J Gastroenterol. 2006;12:4214-8.
31. Thulin L, Tyden G, Nyberg B, Calissendorff B, Hultcrantz R. Reduction of hepatic arterial flow by degradable microspheres in patients with liver tumor. Acta Chir Scand. 1986;152:447-51.
32. Wiggermann P, Heibl M, Niessen C, Muller-Wille R, Gossmann H, Uller W, et al. Degradable starch microspheres transarterial chemoembolisation (DSM-TACE) of HCC: Dynamic Contrast-Enhanced Ultrasonography (DCE-US) based evaluation of therapeutic efficacy using a novel perfusion software. Clin Hemorheol Microcirc. 2012;52:123-9.
33. Ziessman HA, Thrall JH, Gyves JW, Ensminger WD, Niederhuber JE, Tuscan M, et al. Quantitative hepatic arterial perfusion scintigraphy and starch microspheres in cancer chemotherapy. J Nucl Med. 1983;24:871-5.